OA12878A - Method of promoting smoking cessation. - Google Patents

Method of promoting smoking cessation. Download PDF

Info

Publication number: OA12878A
Authority: OA; OAPI
Prior art keywords: smoking; composition; reboxetine; nicotine; effective amount
Prior art date: 2002-07-01

Application number

OA1200400348A

Other languages

English (en)

Inventor

Erik H F Wong

Original Assignee

Pharmacia & Upjohn Co Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-01

Filing date

2003-06-26

Publication date

2006-09-15

2003-06-26 Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc

2006-09-15 Publication of OA12878A publication Critical patent/OA12878A/en

Links

230000005586 smoking cessation Effects 0.000 title claims abstract description 66
230000001737 promoting effect Effects 0.000 title claims abstract description 19
238000000034 method Methods 0.000 title description 18
229960003770 reboxetine Drugs 0.000 claims abstract description 59
CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims abstract description 59
239000003795 chemical substances by application Substances 0.000 claims abstract description 58
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 57
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 56
229960002715 nicotine Drugs 0.000 claims abstract description 54
239000000203 mixture Substances 0.000 claims abstract description 47
230000002708 enhancing effect Effects 0.000 claims abstract description 30
239000000935 antidepressant agent Substances 0.000 claims abstract description 28
229940005513 antidepressants Drugs 0.000 claims abstract description 27
230000001430 anti-depressive effect Effects 0.000 claims abstract description 21
229940044551 receptor antagonist Drugs 0.000 claims abstract description 17
239000002464 receptor antagonist Substances 0.000 claims abstract description 17
239000003401 opiate antagonist Substances 0.000 claims abstract description 16
239000002249 anxiolytic agent Substances 0.000 claims description 34
230000000949 anxiolytic effect Effects 0.000 claims description 34
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 23
229960001058 bupropion Drugs 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 14
239000003826 tablet Substances 0.000 claims description 13
-1 inhalant Substances 0.000 claims description 12
229960002495 buspirone Drugs 0.000 claims description 11
229960005426 doxepin Drugs 0.000 claims description 10
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 10
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 10
239000002775 capsule Substances 0.000 claims description 9
229960003086 naltrexone Drugs 0.000 claims description 9
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 8
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 7
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 claims description 6
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 6
229960003529 diazepam Drugs 0.000 claims description 6
229960004815 meprobamate Drugs 0.000 claims description 6
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 5
WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 claims description 5
WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 5
MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 claims description 5
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 5
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims description 5
229960002464 fluoxetine Drugs 0.000 claims description 5
229960002158 halazepam Drugs 0.000 claims description 5
229960004801 imipramine Drugs 0.000 claims description 5
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 5
229960005297 nalmefene Drugs 0.000 claims description 5
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 5
229960004127 naloxone Drugs 0.000 claims description 5
229960002073 sertraline Drugs 0.000 claims description 5
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 5
XULIXFLCVXWHRF-UHFFFAOYSA-N 1,2,2,6,6-pentamethylpiperidine Chemical compound CN1C(C)(C)CCCC1(C)C XULIXFLCVXWHRF-UHFFFAOYSA-N 0.000 claims description 4
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 4
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims description 4
229960004538 alprazolam Drugs 0.000 claims description 4
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 4
229960003805 amantadine Drugs 0.000 claims description 4
229960002519 amoxapine Drugs 0.000 claims description 4
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims description 4
229960002430 atomoxetine Drugs 0.000 claims description 4
VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 4
229960004782 chlordiazepoxide Drugs 0.000 claims description 4
DXXUGBPKQDTBQW-UHFFFAOYSA-L chlorisondamine Chemical compound [Cl-].[Cl-].ClC1=C(Cl)C(Cl)=C(Cl)C2=C1C[N+](CC[N+](C)(C)C)(C)C2 DXXUGBPKQDTBQW-UHFFFAOYSA-L 0.000 claims description 4
229950002565 chlorisondamine Drugs 0.000 claims description 4
229960003120 clonazepam Drugs 0.000 claims description 4
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 4
229960003914 desipramine Drugs 0.000 claims description 4
BDIVMECULLJBMU-KSSFIOAISA-N erysodine Chemical compound OC1=C(OC)C=C2[C@]34C[C@@H](OC)C=CC3=CCN4CCC2=C1 BDIVMECULLJBMU-KSSFIOAISA-N 0.000 claims description 4
BDIVMECULLJBMU-UHFFFAOYSA-N erysodine Natural products OC1=C(OC)C=C2C34CC(OC)C=CC3=CCN4CCC2=C1 BDIVMECULLJBMU-UHFFFAOYSA-N 0.000 claims description 4
229960004090 maprotiline Drugs 0.000 claims description 4
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 4
229960003793 midazolam Drugs 0.000 claims description 4
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims description 4
229960004535 oxazepam Drugs 0.000 claims description 4
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 4
229950009414 pempidine Drugs 0.000 claims description 4
229960000964 phenelzine Drugs 0.000 claims description 4
229960004856 prazepam Drugs 0.000 claims description 4
229960002601 protriptyline Drugs 0.000 claims description 4
BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims description 4
229960003991 trazodone Drugs 0.000 claims description 4
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 4
HALWUDBBYKMYPW-STOWLHSFSA-M trimethaphan camsylate Chemical compound C1C[C@@]2(CS([O-])(=O)=O)C(=O)C[C@@H]1C2(C)C.C12C[S+]3CCCC3C2N(CC=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 HALWUDBBYKMYPW-STOWLHSFSA-M 0.000 claims description 4
229940029774 trimethaphan camsylate Drugs 0.000 claims description 4
229960001844 tubocurarine Drugs 0.000 claims description 4
JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 claims description 4
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 3
GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 claims description 3
IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 3
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 3
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 3
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 3
229960000836 amitriptyline Drugs 0.000 claims description 3
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 3
239000005557 antagonist Substances 0.000 claims description 3
229960004606 clomipramine Drugs 0.000 claims description 3
229960004362 clorazepate Drugs 0.000 claims description 3
XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 claims description 3
ALSKYCOJJPXPFS-BBRMVZONSA-N dihydro-beta-erythroidine Chemical compound C([C@@H](C[C@@]123)OC)C=C1CCN2CCC1=C3CC(=O)OC1 ALSKYCOJJPXPFS-BBRMVZONSA-N 0.000 claims description 3
PXWINCSLFXUWBZ-UHFFFAOYSA-N dihydro-beta-erythroidine Natural products C1C(=O)OCC2=C1C13CC(OC)C=CC1=CCN3CC2 PXWINCSLFXUWBZ-UHFFFAOYSA-N 0.000 claims description 3
229960000930 hydroxyzine Drugs 0.000 claims description 3
ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 3
229960001785 mirtazapine Drugs 0.000 claims description 3
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 3
239000007922 nasal spray Substances 0.000 claims description 3
229940097496 nasal spray Drugs 0.000 claims description 3
229960001800 nefazodone Drugs 0.000 claims description 3
VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 3
229960001158 nortriptyline Drugs 0.000 claims description 3
229960002296 paroxetine Drugs 0.000 claims description 3
229960003741 tranylcypromine Drugs 0.000 claims description 3
229960002431 trimipramine Drugs 0.000 claims description 3
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 3
229960002655 tubocurarine chloride Drugs 0.000 claims description 3
229960004688 venlafaxine Drugs 0.000 claims description 3
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 3
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 2
229960002866 duloxetine Drugs 0.000 claims description 2
229960004038 fluvoxamine Drugs 0.000 claims description 2
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 2
239000007937 lozenge Substances 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
229940112822 chewing gum Drugs 0.000 claims 1
235000015218 chewing gum Nutrition 0.000 claims 1
229940035742 trimethaphan Drugs 0.000 claims 1
CHQOEHPMXSHGCL-UHFFFAOYSA-N trimethaphan Chemical compound C12C[S+]3CCCC3C2N(CC=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 CHQOEHPMXSHGCL-UHFFFAOYSA-N 0.000 claims 1
230000000391 smoking effect Effects 0.000 description 22
229940005530 anxiolytics Drugs 0.000 description 17
RICLFGYGYQXUFH-UHFFFAOYSA-N buspirone hydrochloride Chemical compound [H+].[Cl-].C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 RICLFGYGYQXUFH-UHFFFAOYSA-N 0.000 description 11
238000002560 therapeutic procedure Methods 0.000 description 11
MHNSPTUQQIYJOT-SJDTYFKWSA-N Doxepin Hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 MHNSPTUQQIYJOT-SJDTYFKWSA-N 0.000 description 10
150000001875 compounds Chemical class 0.000 description 8
241000208125 Nicotiana Species 0.000 description 7
235000002637 Nicotiana tabacum Nutrition 0.000 description 7
238000009472 formulation Methods 0.000 description 7
IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 7
229960002525 mecamylamine Drugs 0.000 description 7
239000008194 pharmaceutical composition Substances 0.000 description 6
235000019505 tobacco product Nutrition 0.000 description 6
229960002861 doxepin hydrochloride Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000003887 narcotic antagonist Substances 0.000 description 4
229940099632 nicotrol Drugs 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
HEYVINCGKDONRU-UHFFFAOYSA-N Bupropion hydrochloride Chemical compound Cl.CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 HEYVINCGKDONRU-UHFFFAOYSA-N 0.000 description 3
208000025569 Tobacco Use disease Diseases 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000012552 review Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000009897 systematic effect Effects 0.000 description 3
229940018503 zyban Drugs 0.000 description 3
CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 2
IKBZAUYPBWFMDI-UHFFFAOYSA-N 5-bromo-4-methoxy-7-methyl-2,3-dihydro-1h-indene Chemical compound C1=C(Br)C(OC)=C2CCCC2=C1C IKBZAUYPBWFMDI-UHFFFAOYSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010057852 Nicotine dependence Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
229960004367 bupropion hydrochloride Drugs 0.000 description 2
239000003086 colorant Substances 0.000 description 2
235000019788 craving Nutrition 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
229940087496 habitrol Drugs 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
229960002237 metoprolol Drugs 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
229940087730 nicorette Drugs 0.000 description 2
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229960004570 oxprenolol Drugs 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
229940009065 wellbutrin Drugs 0.000 description 2
XUSCOHKHRDQKCI-ARFHVFGLSA-N (1S,9R,10R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-13-one Chemical compound C1C(=O)CC[C@H]2[C@]3([H])NCC[C@@]21C1=CC=CC=C1C3 XUSCOHKHRDQKCI-ARFHVFGLSA-N 0.000 description 1
CGTZMJIMMUNLQD-STYNFMPRSA-N (2r)-2-[(r)-(2-ethoxyphenoxy)-phenylmethyl]morpholine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CGTZMJIMMUNLQD-STYNFMPRSA-N 0.000 description 1
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229940123257 Opioid receptor antagonist Drugs 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
206010048010 Withdrawal syndrome Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000012790 adhesive layer Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940072698 ativan Drugs 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
229940015273 buspar Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
QCHSEDTUUKDTIG-UHFFFAOYSA-L dipotassium clorazepate Chemical compound [OH-].[K+].[K+].C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 QCHSEDTUUKDTIG-UHFFFAOYSA-L 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000003457 ganglion blocking agent Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
231100000206 health hazard Toxicity 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
SANOUVWGPVYVAV-UHFFFAOYSA-N isovaleramide Chemical compound CC(C)CC(N)=O SANOUVWGPVYVAV-UHFFFAOYSA-N 0.000 description 1
239000010410 layer Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229960001263 mecamylamine hydrochloride Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
QVRVXSZKCXFBTE-UHFFFAOYSA-N n-[4-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)butyl]-2-(2-fluoroethoxy)-5-methylbenzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCCCNC(=O)C1=CC(C)=CC=C1OCCF QVRVXSZKCXFBTE-UHFFFAOYSA-N 0.000 description 1
229940015769 nicotine chewing gum Drugs 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960005343 ondansetron Drugs 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
229940053544 other antidepressants in atc Drugs 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000697 serotonin reuptake Effects 0.000 description 1
229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000011125 single therapy Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
229940063648 tranxene Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
229940072690 valium Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940074158 xanax Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Addiction (AREA)
Psychiatry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA1200400348A 2002-07-01 2003-06-26 Method of promoting smoking cessation. OA12878A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US39289302P	2002-07-01	2002-07-01

Publications (1)

Publication Number	Publication Date
OA12878A true OA12878A (en)	2006-09-15

Family

ID=30000949

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200400348A OA12878A (en)	2002-07-01	2003-06-26	Method of promoting smoking cessation.

Country Status (22)

Country	Link
US (1)	US20040102440A1 (is)
EP (1)	EP1534254A2 (is)
JP (1)	JP2005531631A (is)
CN (1)	CN1665511A (is)
AP (1)	AP2004003188A0 (is)
AU (1)	AU2003253609A1 (is)
BR (1)	BR0312293A (is)
CA (1)	CA2491549A1 (is)
EA (1)	EA200401584A1 (is)
EC (1)	ECSP045517A (is)
HR (1)	HRP20041194A2 (is)
IL (1)	IL165882A0 (is)
IS (1)	IS7600A (is)
MA (1)	MA27597A1 (is)
MX (1)	MXPA05000296A (is)
NO (1)	NO20045535L (is)
OA (1)	OA12878A (is)
PL (1)	PL373620A1 (is)
RS (1)	RS115204A (is)
TN (1)	TNSN04267A1 (is)
WO (1)	WO2004002463A2 (is)
ZA (1)	ZA200410339B (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE521512C2 (sv)	2001-06-25	2003-11-11	Niconovum Ab	Anordning för administrering av en substans till främre delen av en individs munhåla
PT1578422E (pt)	2002-12-20	2007-06-14	Niconovum Ab	Material particulado contendo nicotina fisicamente e quimicamente estável
HUE034290T2 (en)	2003-04-29	2018-02-28	Orexigen Therapeutics Inc	Preparations containing opioid antagonist and bupropion to affect weight loss
EP1870096A3 (en) *	2003-04-29	2011-04-20	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
ZA200711123B (en)	2005-06-27	2009-08-26	Biovail Lab Int Srl	Modified-release formulations of a bupropion salt
CA2630624C (en)	2005-11-22	2013-08-06	Orexigen Therapeutics, Inc.	Compositions and methods for increasing insulin sensitivity
AU2007224584A1 (en)	2006-03-16	2007-09-20	Niconovum Ab	Improved snuff composition
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
US20070297991A1 (en) *	2006-06-23	2007-12-27	Minu, L.L.C.	Neural conduit agent dissemination for smoking cessation and other applications
KR20170077291A (ko)	2006-11-09	2017-07-05	오렉시젠 세러퓨틱스 인크.	단위 용량 팩키지
EP2170274A1 (en) *	2007-07-02	2010-04-07	Technion Research and Development Foundation, Ltd.	Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage
JP2011521973A (ja)	2008-05-30	2011-07-28	オレキシジェン・セラピューティクス・インコーポレーテッド	内臓脂肪の状態を処置するための方法
US20100069389A1 (en) *	2008-09-06	2010-03-18	Bionevia Pharmaceuticals, Inc.	Novel forms of reboxetine
US20110046116A1 (en)	2009-08-20	2011-02-24	Cukrowski Walter J	Sedative for use during eye surgery
WO2011041451A2 (en) *	2009-09-30	2011-04-07	Harlan Clayton Bieley	Smoking cessation with body weight maintenance and nutritional supplement
ES2762113T3 (es)	2010-01-11	2020-05-22	Nalpropion Pharmaceuticals Inc	Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
TW201217527A (en)	2010-07-09	2012-05-01	Biogen Idec Hemophilia Inc	Processable single chain molecules and polypeptides made using same
LT3730132T (lt)	2012-06-06	2022-08-25	Nalpropion Pharmaceuticals Llc	Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
WO2015054730A1 (en) *	2013-10-14	2015-04-23	Palmaya Pty Ltd	Compositions and methods of administering same
US8969371B1 (en)	2013-12-06	2015-03-03	Orexigen Therapeutics, Inc.	Compositions and methods for weight loss in at risk patient populations
CA2875384A1 (en)	2013-12-20	2015-06-20	AntiOP, Inc.	Intranasal naloxone compositions and methods of making and using same
CN104381577A (zh) *	2014-11-18	2015-03-04	安徽润康保健食品有限公司	一种具有戒烟功能的口香糖
US20200147093A1 (en)	2018-10-15	2020-05-14	Axsome Therapeutics, Inc.	Use of esreboxetine to treat nervous system disorders such as fibromyalgia
AU2020223284A1 (en)	2019-02-17	2021-09-16	Neurawell Therapeutics	Compositions and methods for treatment of depression and other disorders
CA3166250A1 (en)	2020-02-05	2021-08-12	Gregory G. Plucinski	Drug products for intranasal administration and uses thereof
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion
US12565478B1 (en)	2025-01-21	2026-03-03	Axsome Therapeutics, Inc.	(S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1069900E (pt) *	1998-04-09	2005-10-31	Pharmacia & Upjohn Co Llc	Novos tratamentos para disturbios nervosos
SK14502000A3 (sk) *	1998-05-08	2001-05-10	Pharmacia And Upjohn Company	Kombinácie liekov n. a. r. i. (inhibítorov reaktivácie noradrenalínu), výhodne reboxetínu, a pindololu
DE60022692T2 (de) *	1999-07-01	2006-06-22	Pharmacia & Upjohn Co. Llc, Kalamazoo	(S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE10004547A1 (de) *	2000-02-02	2001-08-09	Liedtke Pharmed Gmbh	Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe

2003
- 2003-06-24 US US10/602,447 patent/US20040102440A1/en not_active Abandoned
- 2003-06-26 AU AU2003253609A patent/AU2003253609A1/en not_active Abandoned
- 2003-06-26 OA OA1200400348A patent/OA12878A/en unknown
- 2003-06-26 WO PCT/US2003/016232 patent/WO2004002463A2/en not_active Ceased
- 2003-06-26 EA EA200401584A patent/EA200401584A1/ru unknown
- 2003-06-26 CA CA002491549A patent/CA2491549A1/en not_active Abandoned
- 2003-06-26 AP AP200403187D patent/AP2004003188A0/xx unknown
- 2003-06-26 PL PL03373620A patent/PL373620A1/xx not_active Application Discontinuation
- 2003-06-26 MX MXPA05000296A patent/MXPA05000296A/es not_active Application Discontinuation
- 2003-06-26 JP JP2004517572A patent/JP2005531631A/ja active Pending
- 2003-06-26 EP EP03761901A patent/EP1534254A2/en not_active Ceased
- 2003-06-26 CN CN038156369A patent/CN1665511A/zh active Pending
- 2003-06-26 HR HR20041194A patent/HRP20041194A2/xx not_active Application Discontinuation
- 2003-06-26 BR BR0312293-0A patent/BR0312293A/pt not_active IP Right Cessation
- 2003-06-26 RS YUP-1152/04A patent/RS115204A/sr unknown
2004
- 2004-12-16 IS IS7600A patent/IS7600A/is unknown
- 2004-12-17 NO NO20045535A patent/NO20045535L/no not_active Application Discontinuation
- 2004-12-17 MA MA28018A patent/MA27597A1/fr unknown
- 2004-12-20 IL IL16588204A patent/IL165882A0/xx unknown
- 2004-12-22 ZA ZA200410339A patent/ZA200410339B/en unknown
- 2004-12-28 EC EC2004005517A patent/ECSP045517A/es unknown
- 2004-12-30 TN TNP2004000267A patent/TNSN04267A1/fr unknown

Also Published As

Publication number	Publication date
AU2003253609A1 (en)	2004-01-19
ZA200410339B (en)	2006-07-26
ECSP045517A (es)	2005-03-10
MA27597A1 (fr)	2005-11-01
JP2005531631A (ja)	2005-10-20
CN1665511A (zh)	2005-09-07
EA200401584A1 (ru)	2005-08-25
AP2004003188A0 (en)	2004-12-31
US20040102440A1 (en)	2004-05-27
RS115204A (sr)	2007-02-05
MXPA05000296A (es)	2005-08-19
BR0312293A (pt)	2005-04-12
IS7600A (is)	2004-12-16
WO2004002463A2 (en)	2004-01-08
NO20045535L (no)	2005-01-27
PL373620A1 (en)	2005-09-05
CA2491549A1 (en)	2004-01-08
HRP20041194A2 (en)	2005-06-30
WO2004002463A3 (en)	2004-02-19
TNSN04267A1 (fr)	2007-03-12
IL165882A0 (en)	2006-01-15
EP1534254A2 (en)	2005-06-01

Publication	Publication Date	Title
OA12878A (en)	2006-09-15	Method of promoting smoking cessation.
CA2305799C (en)	2008-12-23	Composition for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
US20020019421A1 (en)	2002-02-14	Compositions and therapy for substance addiction
EA003142B1 (ru)	2003-02-27	Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
WO2005030187A2 (en)	2005-04-07	Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
JP2009517393A (ja)	2009-04-30	不安症の治療方法
JP2005500298A (ja)	2005-01-06	嗜癖物質または麻薬に対する依存症を医薬を用いて処置するための活性成分の組み合わせ
CA2429047A1 (en)	2002-05-23	Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
Glynn et al.	2009	Update on smoking cessation therapies
CZ301210B6 (cs)	2009-12-09	Použití desoxypeganinu k ošetrování klinické deprese
KR20050016679A (ko)	2005-02-21	금연을 촉진시키는 방법
HUP0401013A2 (hu)	2004-08-30	Hatóanyag-kombináció nikotinfüggőség gyógyszeres kezelésére és ezt tartalmazó gyógyszerkészítmény
WO2000006139A2 (en)	2000-02-10	Use of moclobemide and metabolites for treating and preventing substance abuse
HK1076736A (en)	2006-01-27	Method of promoting smoking cessation
TW574037B (en)	2004-02-01	Nicotine addiction treatment
CA2523331A1 (en)	2004-11-11	Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse
HK1034662B (en)	2005-04-08	Composition for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
AU5335000A (en)	2000-11-09	New treatment using phenethylamine derivatives